Treatment of Advanced Melanoma: Past, Present and Future

被引：20

作者：

Fujimura, Taku ^{[1
]}

Kambayashi, Yumi ^{[1
]}

Ohuchi, Kentaro ^{[1
]}

Muto, Yusuke ^{[1
]}

Aiba, Setsuya ^{[1
]}

机构：

[1] Tohoku Univ, Dept Dermatol, Grad Sch Med, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan

来源：

LIFE-BASEL | 2020年 / 10卷 / 09期

关键词：

metastatic melanoma; BRAF inhibitors; MEK inhibitors; immune checkpoints inhibitors; combination therapy; ADVANCED METASTATIC MELANOMA; LIGAND; EXPRESSION; INTERFERON-ALPHA; PHASE-III; JAPANESE PATIENTS; OPEN-LABEL; TARGETED THERAPY; SURVIVAL RATES; DOUBLE-BLIND; NIVOLUMAB;

D O I：

10.3390/life10090208

中图分类号：

Q [生物科学];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

Therapeutic options for treating advanced melanoma are progressing rapidly. Until six years ago, the regimen for treating advanced melanoma mainly comprised cytotoxic agents such as dacarbazine, and type I interferons. Since 2014, anti-programmed cell death 1 (PD1) antibodies have become recognized as anchor drugs for treating advanced melanoma with or without additional combination drugs such as ipilimumab. In addition, v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase inhibitors in combination with mitogen-activated protein kinase kinase (MEK) inhibitors are among the most promising chemotherapeutic regimens for treating advanced BRAF-mutant melanoma, especially in patients with low tumor burden. Since anti-PD1 antibodies are widely applicable for the treatment of both BRAF wild-type and mutated advanced melanomas, several clinical trials for drugs in combination with anti-PD1 antibodies are ongoing. This review focuses on the development of the anti-melanoma therapies available today, and discusses the clinical trials of novel regimens for the treatment of advanced melanoma.

引用

页码：1 / 15

页数：15

共 50 条

[31] Non-melanoma skin cancer: Past, present, and future
Otley, CC
[J]. CURRENT PROBLEMS IN DERMATOLOGY-US, 2001, 13 (02): : 109 - 113
[32] CTLA-4 Blockade for Melanoma: Past, Present and Future
Wolchok, J.
[J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 : 7 - 7
[33] CONSTITUTIONAL RIGHT TO TREATMENT - PAST, PRESENT, AND FUTURE
WALLACH, S
[J]. PROFESSIONAL PSYCHOLOGY, 1976, 7 (04): : 453 - 467
[34] The past, present, and future of behavioral obesity treatment
Chao, Ariana M.
Moore, Molly
Wadden, Thomas A.
[J]. INTERNATIONAL JOURNAL OF OBESITY, 2024,
[35] Immunocytokines for cancer treatment: past, present and future
Neri, Dario
Sondel, Paul M.
[J]. CURRENT OPINION IN IMMUNOLOGY, 2016, 40 : 96 - 102
[36] SURGICAL TREATMENT OF COLITIS - PAST, PRESENT, AND FUTURE
GOLIGHER, JC
[J]. ANNALS OF THE ROYAL COLLEGE OF SURGEONS OF ENGLAND, 1978, 60 (03) : 258 - 260
[37] Psoriasis and Treatment: Past, Present and Future Aspects
Reid, Claire
Griffiths, Christopher E. M.
[J]. ACTA DERMATO-VENEREOLOGICA, 2020, 100 : 69 - 79
[38] Intracranial Atherosclerosis Treatment Past, Present, and Future
Flusty, Brent
de Havenon, Adam
Prabhakaran, Shyam
Liebeskind, David S.
Yaghi, Shadi
[J]. STROKE, 2020, 51 (03) : E49 - E53
[39] Peanut Allergy Treatment: Past, Present, and Future
Keller, Tracey A.
Amsden, Guy W.
[J]. JOURNAL OF PHARMACY TECHNOLOGY, 2005, 21 (01) : 3 - 7
[40] Drug treatment of delirium: Past, present and future
Bourne, Richard S.
Tahir, Tayyeb A.
Borthwick, Mark
Sampson, Elizabeth L.
[J]. JOURNAL OF PSYCHOSOMATIC RESEARCH, 2008, 65 (03) : 273 - 282

← 1 2 3 4 5 →